Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • CardieX has appointed two new board members to support its global expansion strategy
  • Chris Dax has been appointed Vice President and Sean Merrit has been appointed Director of Product Innovation to support
  • With a new sales and marketing strategy, CardieX is targeting a minimum 20 per cent increase in sales for the FY2020 period

CardieX has appointed two new board members to support its global expansion strategy and sales growth.

SphygmoCor is the primary focus of AtCor’s business. The SphygmoCor technology device helps researchers detect and target organ damage and manage cardiovascular and renal disease in the early stages.

This is just one of the products CardieX and its subsidiary are driving sales for. The company is targeting at least a 20 per cent increase in sales for the 2020 period

Senior health executive, Chris Dax has been selected as the new Vice President of Operations to assist with the company’s plan. He has considerable pharmaceutical, biological and medical device, commercial and general management experience.

“Chris Dax is a 25-year medical device marketing and sales executive who will be primarily focused on expanding sales and marketing of AtCor’s medical device business as well as “new product” go-to-market strategy,” CEO Craig Cooper said.

CardieX has also appointed Sean Merrit as the Director of Product Innovation to assist with the launch of new products into the global health market.

Most recently, Sean worked for Cercacor’s consumer non-invasive patient technology device business. He was responsible for engineering, designing and product development for Cercacor’s device solutions.

“They have both hit the ground running and are already contributing significantly to our sales, revenue, product development, and marketing strategies for FY2020 and beyond,” Craig said.

CDX by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…
The Market Herald Video

" Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (ASX:IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing…

" Microba Life Sciences (ASX:MAP) partners with Midnight Health

Microba Life Sciences (ASX:MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to…